

## Progestogen - Etonogestrel (Nexplanon®/Implanon®)

Fact Sheet Compiled by: Hester van Bolhuis

Last Updated: 2020

Fact Sheet Reviewed by: (1) Gidona Goodman (2) Marno Wolters

The EAZA RMG encourages all institutions using contraception to supplement any contraceptive bout with behavioural and hormone monitoring. For more information, please contact contraception@chesterzoo.org

hormone monitoring. For more information, please contact <a href="mailto:contraception@chesterzoo.org">contraception@chesterzoo.org</a>			
Commercial Name:	Nexplanon®/Implanon® (Organon)		
Contraceptive Product:	Etonogestrel 68 mg		
Product Category:	Progestogen		
Product Availability:	Available through human drug distributors; registered as Nexplanon® in EEA member states: Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Hungary, Iceland, Ireland, Italy, Luxembourg, Malta, the Netherlands, Norway, Poland, Portugal, Slovakia, Spain, Sweden, UK		
Restrictions and/or permit required by Importing Country:	The EAZA RMG recommends always checking with your local licensing authority		
Mechanism of action:	Inhibition of ovulation and hindering of spermatozoa passage by influence on cervical mucosa		
Product information	Product used to suppress oestrus in females.  Nexplanon® replaced Implanon® in 2010 and they are bioequivalent; however Nexplanon® contains a radiopaque ingredient (barium sulphate) and can be detected by X-ray.		
Delivery Route and dose:	Subcutaneous implant, see taxon sheets for sites of insertion. Full immobilization recommended for insertion. The implants can be cut in 2, 3 or 4 pieces under sterile conditions. Dividing of the implant doesn't affect the duration of the effect. Dose is taxon specific (see taxon sheets) and depends on the weight of the animal. The presence and location of the implant should be checked every time the animal is handled. An implant can get lost by overgrooming or after wrong insertion  The EAZA RMG recommends always reading the manufacturer's data sheet		
Females			
Latency to effectiveness:	In general inhibition of ovulation after 1 day when inserted on day 1-5 of cycle when replacing oral progestagen. As the right stage during menstrual cycle is often unknown, it is advised to use other contraceptive methods for at least 7 days after insertion of the implant		
Oestrus cycles during contraceptive treatment:	Oestrus is inhibited. Sexual swellings and menstruation in non-human primates are more or less present with regular cyclicity.		
Managing of initial stimulation phase:	N/A		
Use during pregnancy:	Implanon®/Nexplanon® is not recommended for use in pregnant animals because of the risk of prolonged gestation, still-birth or abortion.  Progestagens do not appear to interfere with parturition in primates, but this		
Use during lactation:	is a taxon-specific phenomenon.  Contraindicated. It does not affect lactation, but etonogestrel is excreted in milk		
Use in prepubertals or juveniles:	Data deficient		



FΔ7Δ R	enrodu	ctive N	lanagement (	Groun

	EAZA REPRODUCTIVE Management Group		
Use in seasonal breeders:	Recommended: when given at least 2 weeks before expected breeding season		
Duration	2.5 -3 years in various primates, however may be taxon specific (see taxon sheets)		
Reversibility	Cases of reversibility have been demonstrated; however, this is individual and taxon dependant, please <b>see taxon sheets</b>		
Effects on Behaviour	Data deficient		
Effects on sexual physical characteristics	<b>See taxon sheets</b> . Sexual swellings are more or less present in non-human primates		
Males			
Latency to effectiveness:	N/A		
Use in prepubertals or juveniles:	N/A		
Use in seasonal breeders:	N/A		
Duration and Reversibility	N/A		
Effects on Behaviour	N/A		
Effects on sexual physical characteristics	N/A		
General:			
Side effects	Possible weight gain, possible increased or decreased frequency of bleeding during menstruation  The EAZA RMG recommends always reading the manufacturer's data sheet		
Warnings	Interaction with other drugs are known to occur and may influence protection against pregnancy  The EAZA RMG recommends always reading the manufacturer's data sheet		
Reporting Requirements: In order to increase our knowledge of the efficacy of contraception methods it is recommended that all individuals on contraception be reported to the EAZA RMG			

## **References:**

- **1)** E. Klokkemeyer 2002. Norplant and Implanon. A review about two contraceptive implants and their physiological effects on primates (student report UVA, Amsterdam).
- **2)** Organon (April 2006). "Implanon SPC (Summary of Product Characteristics)". http://emc.medicines.org.uk/emc/assets/c/html/displaydoc.asp?documentid=5382. Retrieved 2007-04-15.

**Disclaimer:** The EAZA RMG endeavours to provide correct and current information on contraception from various sources. As these are prescription only medicines it is the responsibility of the veterinarian to determine the dosage and best treatment for an individual animal under their care. The EAZA RMG can therefore not be held liable for any injury, damage or contraception failure in an animal.